Therefore, responses to venetoclax are broader and more durable when the drug is combined with other agents that promote cell death through distinct mechanisms.39 In DLBCL, venetoclax combined with the standard of care (R-CHOP) is more effective than venetoclax monotherapy and components of the CHOP regimen can increase sensitivity to venetoclax in vitro.40,41 Incorporation of additional targeted agents has potential to further improve responses. The gene discussed is DDIT3; the disease is diffuse large B-cell lymphoma.